Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aticaprant (CERC-501) Augmentation in TRD
NCT01913535Phase 2Terminated
- Sponsor
- Massachusetts General Hospital
- Start
- Sep 2013
- Primary completion
- Jan 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of aticaprant in major depressive disorder (MDD), sponsored by Massachusetts General Hospital. Started Sep 2013; status: terminated.
02
Drugs
aticaprant
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT01913535.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01913535.